Laura Williams Sells 50,000 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ:ARDX) insider Laura Williams sold 50,000 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.98, for a total value of $349,000.00. Following the sale, the insider owned 361,563 shares in the company, valued at approximately $2,523,709.74. The trade was a 12.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ardelyx Stock Up 10.6%

Shares of NASDAQ ARDX opened at $7.74 on Friday. The company has a quick ratio of 4.11, a current ratio of 4.41 and a debt-to-equity ratio of 1.31. The company has a market cap of $1.88 billion, a P/E ratio of -33.65 and a beta of 0.56. Ardelyx, Inc. has a 52 week low of $3.21 and a 52 week high of $8.05. The business has a 50-day simple moving average of $5.89 and a two-hundred day simple moving average of $5.50.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.06. Ardelyx had a negative net margin of 14.20% and a negative return on equity of 36.91%. The firm had revenue of $110.33 million for the quarter, compared to the consensus estimate of $100.44 million. The firm’s revenue was up 14.6% on a year-over-year basis. Research analysts anticipate that Ardelyx, Inc. will post -0.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Piper Sandler upgraded shares of Ardelyx from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $16.00 in a research report on Thursday. Wedbush lowered Ardelyx from an “outperform” rating to a “hold” rating in a research note on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Ardelyx in a research report on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of Ardelyx in a report on Friday, October 31st. Finally, TD Cowen lifted their price target on Ardelyx from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.80.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Company reported preliminary 2025 product revenue of about $378 million and issued a bullish strategic outlook for 2026 — this is the main fundamental driver supporting the stock’s rally. Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
• Positive Sentiment: Piper Sandler upgraded Ardelyx citing ongoing strength for Ibsrela, which boosted investor confidence and helped extend the share rally. Ardelyx extends rally as Piper Sandler upgrades on Ibsrela strength
• Positive Sentiment: Unusual options activity: investors bought 3,598 call options (about +128% vs. typical daily call volume), indicating short-term bullish positioning by derivatives traders.
• Neutral Sentiment: Media and equity research pieces are re‑running valuation and strategy takes after the recent move — these analyses can amplify momentum but are not new company fundamentals. Assessing Ardelyx (ARDX) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Additional commentary examines shifting valuation assumptions and new Ibsrela commercial targets — useful for modelling upside but dependent on execution and duration of uptake. Why The Ardelyx ARDX Story Is Shifting On New Ibsrela Targets And Valuation Assumptions
• Negative Sentiment: Insider selling: Laura A. Williams sold 50,000 shares on Jan. 8 at an average $6.98 (~$349k), reducing her stake by ~12.15% — such disclosure can create short‑term headwinds or caution among some investors. Insider Form 4 (Laura A. Williams)

Hedge Funds Weigh In On Ardelyx

Hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its holdings in shares of Ardelyx by 118.2% during the 1st quarter. Millennium Management LLC now owns 6,465,262 shares of the biopharmaceutical company’s stock valued at $31,744,000 after buying an additional 3,501,782 shares in the last quarter. Marshall Wace LLP boosted its stake in Ardelyx by 34.2% in the second quarter. Marshall Wace LLP now owns 11,250,652 shares of the biopharmaceutical company’s stock worth $44,103,000 after buying an additional 2,866,843 shares in the last quarter. Bank of America Corp DE grew its position in Ardelyx by 88.8% during the second quarter. Bank of America Corp DE now owns 5,527,988 shares of the biopharmaceutical company’s stock valued at $21,670,000 after acquiring an additional 2,600,080 shares during the last quarter. Vanguard Group Inc. grew its position in Ardelyx by 14.6% during the third quarter. Vanguard Group Inc. now owns 18,369,321 shares of the biopharmaceutical company’s stock valued at $101,215,000 after acquiring an additional 2,337,672 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Ardelyx by 188.5% during the first quarter. AQR Capital Management LLC now owns 1,573,063 shares of the biopharmaceutical company’s stock worth $7,724,000 after acquiring an additional 1,027,814 shares in the last quarter. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.